Vaniam Group has appointed Cherie Myatt as Interim President, effective immediately, as the oncology-focused partner to biopharma companies reinforces its long-term commitment to value creation and leadership continuity.
In the role, Myatt will provide executive leadership across the organization, guiding strategic direction, supporting operational excellence, and ensuring continuity as the company advances its growth strategy and long-term vision. She will work closely with the leadership team to strengthen organizational alignment and maintain momentum during the transition period.
Alongside her new responsibilities, Myatt will continue to lead Vaniam Group’s Patient Engagement and Rare Disease capabilities, where she provides strategic oversight and helps shape the firm’s long-term approach to patient-centric innovation across the life sciences ecosystem.
Myatt brings experience as a founder, chief executive, and enterprise operator. She founded and served as CEO and owner of CM Group, which was acquired by OPEN Health. Following the acquisition, she led and scaled patient engagement capabilities within the global organization, blending entrepreneurial leadership with enterprise-scale operations. She is recognized for building high-performing teams, navigating complex organizational transitions, and translating strategy into sustainable impact.
The interim appointment underscores Vaniam Group’s focus on thoughtful leadership, stability, and sustained value creation as it continues expanding its oncology intelligence platform and broader capabilities.
Based in the life sciences sector, Vaniam Group partners with biopharma companies operating in complex, high-science medicine. With deep expertise in oncology and hematology, the firm supports clients in interpreting evolving data, emerging insights, and real-world dynamics to drive confident decision-making and program advancement. While oncology remains its core focus, the company applies the same scientific rigor and integrated data-driven approach to other therapeutic areas where complexity and stakes remain high.
KEY QUOTES:
“I’m excited to help shape the next phase of Vaniam Group’s growth. As the organization continues to expand, my focus is on strengthening how we bring insights, engagement, and execution together, so our work scales, our oncology intelligence platform integrates, and our impact for clients continues to deepen. I’m proud to work alongside this team as we build what’s next for Vaniam Group.”
Cherie Myatt, Interim President, Vaniam Group
“Cherie is a proven leader with a rare combination of founder insight and enterprise operating experience. Her appointment as Interim President reflects the confidence we have in her judgment, leadership, and ability to guide our organization with clarity and stability.”
Deanna van Gestel, Chief Executive Officer, Vaniam Group
